Growing Number of Regulatory Approvals Will Aid Growth of the Global Diabetic Neuropathy Market

The global diabetic neuropathy market is anticipated to drive due to high prevalence of diabetic neuropathy, majorly in diabetic patients, all over the world. Some of the aspects which have a direct positive impact on the diabetic neuropathy market are

  • Surge in prevalence of diabetes owing to sedentary lifestyle
  • Increase in obese populace owing to improper diet
  • Expansion in awareness pertaining to diagnosis & treatment of diabetes.

Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=4698

The peripheral neuropathy disorder category is likely to witness surge in usage of diabetic neuropathy formulations. The scope of peripheral neuropathy drugs is slated to increase, as the treatment is at present confined on handling pain instead of nerves regeneration. Additionally, under diagnoses of patients with peripheral neuropathic are likely to widen prospects of these drugs. Estimates indicate an optimistic 5.9% CAGR and a market share higher than 50%.

As per recent study by Fact.MR’s, the global diabetic neuropathy market is poised to record a moderate CAGR of 5.6% amid the estimated period of 2020-2025. Increasing insurance coverage to neuropathic pain drug players is anticipated to continue to amplify market the prospects.

How will Authorization of Novel Drugs to Impulse Revenue Expansion of Diabetic Neuropathy Market?

Diabetes remains the prevalent chronic ailment, impacting millions of individuals across the globe. Imbalanced diets and changing lifestyles are the key factors accountable for increased cases of diabetes. Since 2019, around one-tenth of the world’s populace suffered from diabetes. Accordingly, there has been an increase in diabetic treatment, with major pharmaceutical companies investing highly in emerging anti-diabetic formulations.

The endorsement of novel drugs for the diabetic neuropathic pain treatment has prompted prolific growth in the diabetic drugs market. The FDA accepted Nucynta ER for the neuropathic pain therapy of caused by diabetes. Lyrica, another drug, has in addition been accepted for neuropathic pain therapy in over 130 nations. As a result of these trends, the worldwide market for diabetic neuropathy is projected to expand at a 5.6% CAGR amid the assessment period.

Explore 96 tables and 116 figures in the study. Request ToC of the report at-

https://www.factmr.com/report/4698/diabetic-neuropathy-market

Majority of the market players conclude that a dearth of medicines is not projected amid the assessment period, owing to close observation of supply chain for probable impacts on the medicines sale. On the other hand, delays in processing of orders are anticipated to a shift to a remote workforce.

How big opportunities will Asia Pacific will Offer Market Players?

North America’s diabetic neuropathy is anticipated to account for more than 2/5th of the overall market value. Growing percentage of patients receiving treatment and getting diagnosed for diabetic neuropathy as well as government efforts to fund research for new therapies and drugs will be impelling growth. The regional market is anticipated to growth 1.4X amid the projected period.

Asia Pacific reflects healthy expansion prospects, due to a huge patient pool ensuing from poor dietary habits together with fast expansion of healthcare infrastructure. The regional market is projected to expand 1.5X, accounting for more than 1/5th of the worldwide diabetic neuropathy market amid the projected period.

Explore Fact.MR's Comprehensive Coverage on Healthcare Landscape

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai, United Arab Emirates
MARKET ACCESS DMCC Initiative

Back to news